Mon, April 17, 2023
Sun, April 16, 2023
Fri, April 14, 2023
Thu, April 13, 2023
Wed, April 12, 2023
Tue, April 11, 2023

David Macdonald Maintained (AMED) at Strong Buy with Decreased Target to $115 on, Apr 13th, 2023


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-decreased-target-to-115-on-apr-13th-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

David Macdonald of Truist Securities, Maintained "Amedisys, Inc." (AMED) at Strong Buy with Decreased Target from $130 to $115 on, Apr 13th, 2023.

David has made no other calls on AMED in the last 4 months.



There are 8 other peers that have a rating on AMED. Out of the 8 peers that are also analyzing AMED, 3 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Scott Fidel of "Stephens & Co." Reiterated at Hold and Held Target at $103 on, Tuesday, March 14th, 2023
  • Steve Valiquette of "Barclays" Initiated at Hold and Held Target at $93 on, Monday, March 13th, 2023
  • Whit Mayo of "SVB Leerink" Maintained at Hold with Decreased Target to $85 on, Thursday, January 5th, 2023


These are the ratings of the 5 analyists that currently disagree with David


  • Bill Sutherland of "Benchmark" Reiterated at Strong Buy and Held Target at $115 on, Tuesday, March 14th, 2023
  • Jonathan Yong of "Credit Suisse" Reiterated at Buy and Held Target at $115 on, Monday, February 27th, 2023
  • Ben Hendrix of "RBC Capital" Maintained at Buy with Decreased Target to $111 on, Tuesday, February 21st, 2023
  • Mark Miller of "Benchmark" Maintained at Strong Buy with Decreased Target to $115 on, Thursday, February 16th, 2023
  • Colin Rusch of "Oppenheimer" Maintained at Buy with Decreased Target to $125 on, Thursday, January 19th, 2023

Publication Contributing Sources